DMAC (DiaMedica Therapeutics) OCF Yield %: -9.02 (As of Jun. 24, 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $6.36
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics OCF Yield %?

DiaMedica Therapeutics DMAC +1.75% 31 OCF Yield % is -9.02 as of Jun. 24, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, DiaMedica Therapeutics ranks worse than 51.9% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, DiaMedica Therapeutics's Trailing 12-Month Cash Flow from Operations is $-31.00 Mil, and Market Cap is $343.77 Mil. Therefore, DiaMedica Therapeutics's OCF Yield % for today is -9.02%.

The historical rank and industry rank for DiaMedica Therapeutics's OCF Yield % or its related term are showing as below:

DMAC' s OCF Yield % Range Over the Past 10 Years
Min: -71.98   Med: -20.41   Max: -6.92
Current: -9.02


During the past 13 years, the highest OCF Yield % of DiaMedica Therapeutics was -6.92%. The lowest was -71.98%. And the median was -20.41%.

DMAC's OCF Yield % is ranked worse than
51.9% of 1418 companies
in the Biotechnology industry
Industry Median: -8.55 vs DMAC: -9.02

DiaMedica Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


DiaMedica Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


DiaMedica Therapeutics OCF Yield % Related Terms


DiaMedica Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics OCF Yield % Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.42 -27.55 -17.37 -9.49 -6.79

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.60 -18.09 -7.32 -7.26 -9.96

DMAC vs BCYC, RZLT, ABEO: OCF Yield % Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's OCF Yield % falls into.


DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

DiaMedica Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-29.062 / 427.78632
=-6.79%

DiaMedica Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-9.082 * 4 / 364.78791
=-9.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -9.02 mean?
DiaMedica Therapeutics (DMAC) has a OCF Yield % of -9.02 as of Jun. 24, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #736 out of 1418 companies in the Biotechnology industry, placing it in the top 51.9%.
Is DiaMedica Therapeutics' OCF Yield % too high?
DiaMedica Therapeutics' current OCF Yield % is -9.02. Based on the distribution chart, DiaMedica Therapeutics ranks #736 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' OCF Yield % compare to BCYC and RZLT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #736 out of 1418 companies for OCF Yield %. This places DiaMedica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current OCF Yield % is -9.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current OCF Yield % of -9.02. The current OCF Yield % is -9.02. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current OCF Yield % is -9.02 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.36
Price